TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The investigational LB6V Lyme disease vaccine showed 73.2% efficacy in the phase III trial’s evaluable population, but its confidence interval did not meet the prespecified success threshold. A modified intent-to-treat analysis produced a 74.8% efficacy estimate whose lower confidence bound narrowly cleared the threshold. The results were presented at IDWeek; durability and the need for boosters remain concerns.
The investigational LB6V Lyme disease vaccine showed an estimated 73.2% efficacy in a late-stage trial’s evaluable population but missed the study’s preset statistical success threshold, according to results presented October 27 at the IDWeek annual meeting. A modified intent-to-treat analysis narrowly cleared that threshold, leaving the vaccine’s efficacy signal encouraging but not conclusive under the primary analysis.
Among participants aged 5 years and older in the evaluable population, Lyme disease was diagnosed in four people who received four vaccine doses and 15 who received placebo. The resulting efficacy estimate was 73.2%, with a 95% confidence interval of 15.8% to 93.5%. The trial required the lower end of that interval to exceed 20%, so the primary analysis did not meet the predefined criterion.
In a modified intent-to-treat analysis, efficacy was estimated at 74.8%, with a 95% confidence interval of 21.7% to 93.9%—just above the 20% lower-bound threshold. Paul Auwaerter, MD, of Johns Hopkins University School of Medicine, presented the findings. The two analyses differ in which participants are included; the reported results do not, by themselves, resolve how regulators would weigh the discrepancy.
The VALOR trial enrolled about 9,400 people at elevated risk in the United States, Canada and five European countries. Participants received four doses of LB6V or placebo, with the study spanning three Lyme disease seasons from 2022 through 2025. The primary efficacy period began 28 days after the fourth dose and continued through the end of a Lyme disease season.
A Narrow Statistical Divide
The results matter because no Lyme disease vaccine is currently available, despite the disease’s substantial burden in the United States. The source report says more than 80,000 cases are reported to the CDC annually, while an estimated 476,000 people receive treatment each year. Lyme disease is spread by infected blacklegged ticks and can cause fever, headache, fatigue and a characteristic rash; untreated infection can affect joints, the heart and the nervous system.
The trial’s split outcome leaves a practical and regulatory question: the vaccine produced fewer observed cases among vaccinated participants, but the primary analysis did not satisfy its prespecified statistical rule. The modified analysis did, narrowly. That distinction is important for judging the evidence and should not be reduced to a simple declaration that the trial either succeeded or failed.
Durability is another concern. Reported efficacy fell from 73.2% in the second season after the four-dose course to 18.6% in the third, with a very wide confidence interval of -220.0% to 80.4%. This estimate is imprecise, but the decline may affect how a vaccine would need to be scheduled if later evidence supports its use.
Products Worth Considering
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
Oura Ring 5 Smart Ring – Silver – Size 10
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
How LB6V Was Tested
LB6V, previously known as VLA15, is an adjuvanted protein-subunit vaccine designed to target six serotypes across four Borrelia species common in Europe and North America. The proposed mechanism is that vaccinated people pass antibodies to ticks during a bite; those antibodies can inhibit Borrelia burgdorferi in the tick and help prevent transmission. The vaccine had shown immunogenicity and appeared safe in two phase II trials, according to the report.
VALOR recruited people considered at increased risk because of their occupation, home environment or leisure activities. Participants received doses at baseline, two months, approximately five to nine months, and about 18 months. The median age was 47, 52% were female, and 97% had at least two Lyme disease risk factors. These details describe the study group and do not establish how results would apply to every population.
The United States previously had a Lyme vaccine: the FDA approved recombinant vaccine LYMErix in 1998. Its manufacturer withdrew it from the market in 2002 amid concerns about side effects and declining sales, according to the report. That history provides context for the lack of a currently available vaccine, but does not determine LB6V’s safety or prospects.
“Overall, I do think this vaccine has the potential to lower the Lyme disease burden.”
— Paul Auwaerter, MD, Johns Hopkins University School of Medicine, speaking at IDWeek
Questions About Durability and Evidence
The trial results do not settle whether LB6V will be considered successful for regulatory purposes. The evaluable-population analysis missed the predefined threshold, while the modified intent-to-treat result cleared it by a small margin. The source report does not provide a regulatory decision, agency assessment or complete explanation of how the modified analysis might affect next steps.
The third-season estimate also carries substantial uncertainty: its 95% confidence interval ranged from -220.0% to 80.4%. Antibody levels fell over the same period, but the reported association does not establish a precise duration of protection or prove what booster schedule would work. Long-term efficacy and the need for repeat doses remain unresolved.
On safety, adverse events were reported in 58.8% of vaccine recipients and 52.6% of placebo recipients. Treatment-related events that led to withdrawal occurred in 0.3% and 0.1%, respectively; newly diagnosed chronic medical conditions were reported in 9.6% and 9.5%. Fatigue, headache, muscle and joint pain, and injection-site reactions were more common with the vaccine. These trial figures do not, on their own, establish how the overall benefit-risk assessment will be judged.
Next Steps for LB6V
Further analysis and any decisions by the vaccine developers or regulators will determine whether the trial results support a submission, additional studies or changes to the dosing plan. The source report does not announce a filing, approval or timeline. Readers should treat the reported findings as clinical-trial results, not as an available vaccination option.
Researchers may also examine whether antibody measurements can help predict protection in future studies, as Auwaerter suggested. Any immunobridging approach would need to be supported by further evidence. The key questions ahead are whether protection can be sustained across Lyme disease seasons, whether boosters are needed, and how the two efficacy analyses are weighed.
Key Questions
Did the Lyme vaccine trial meet its main success threshold?
Not in the evaluable-population analysis. Its 73.2% efficacy estimate had a 95% confidence interval of 15.8% to 93.5%, below the required lower bound of more than 20%. A modified intent-to-treat analysis narrowly passed, with a lower bound of 21.7%.
How many Lyme disease cases were reported in the evaluable group?
The report counted four cases among vaccine recipients and 15 among placebo recipients in the evaluable population aged 5 and older.
Is LB6V available to the public?
The source describes LB6V as an investigational vaccine and does not report an approval or public availability. The trial results alone do not make it an available vaccination option.
Does the vaccine appear to protect for multiple seasons?
The reported efficacy estimate fell from 73.2% in the second season to 18.6% in the third, but the third-season confidence interval was very wide. The duration of protection and whether boosters are needed remain uncertain.
What side effects were reported?
Fatigue, headache, muscle pain, joint pain and injection-site pain, redness and swelling were more likely among vaccine recipients than placebo recipients. Adverse events overall were reported in 58.8% of vaccine recipients and 52.6% of placebo recipients.
Source: medpagetoday.com
